北京安健熹

Anjianxi Biotechnology is a Chinese biopharmaceutical company focused on the research and development of innovative metabolic and endocrine therapies. The company specializes in developing next-generation multi-target agonists, particularly focusing on GLP-1, GIP, and Glucagon receptor pathways for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Anjianxi aims to optimize drug efficacy and safety profiles through advanced molecular design and formulation technologies. The company is currently advancing several candidates through the pre-clinical and early development stages to address the growing global burden of metabolic diseases.